Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC

October 12th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses how PD-L1 testing may have played a role in the survival differences between frontline pembrolizumab and nivolumab in non–small-cell lung cancer (NSCLC).

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

October 11th 2016

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC

October 11th 2016

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

Dr. Wistuba on Maximizing Outcomes With Limited Tissue in Lung Cancer

October 11th 2016

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.

Nivolumab Misses PFS Endpoint in First-Line Advanced NSCLC

October 10th 2016

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.

Atezolizumab Significantly Extends Survival in NSCLC

October 10th 2016

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC

October 9th 2016

Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.

Frontline Pembrolizumab Data Is Practice Changing for NSCLC

October 9th 2016

Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.

Dr. Bastholt on Lenvatinib in NSCLC

October 8th 2016

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

Neoadjuvant Anti-PD-1 Therapy Active in NSCLC

October 7th 2016

Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

Optimal Role of PD-L1 Still Unclear in NSCLC

October 6th 2016

Tracey L. Evans, MD, shares her perspective on the role of PD-L1 testing in lung cancer. She also discusses the role of liquid biopsies and other assays that could possibly be on the horizon.

Efforts Continue to Refine Use of Checkpoint Inhibitors in NSCLC

October 5th 2016

Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.

Dr. Stephans on Treatment for Oligometastatic Lung Cancer

October 5th 2016

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

FDA Grants Alectinib Breakthrough Designation for Frontline ALK+ NSCLC

October 4th 2016

The FDA has granted a breakthrough therapy designation to alectinib (Alecensa) as a frontline treatment for patients with ALK-positive non–small cell lung cancer.

Dr. Bauer on Rovalpituzumab Tesirine in SCLC

October 4th 2016

Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Langer Lends Insight on Burgeoning Lung Cancer Developments, Challenges

October 3rd 2016

From optimal therapies for patients with non-driver adenocarcinoma, to studying the biology of squamous cell non–small cell lung cancer, to exploring novel combination regimens, to predicting the risk of mortality, the field of lung cancer is undergoing tremendous changes, explained Corey J. Langer, MD.

Dr. Pennell on Unique Treatment-Related Toxicities in Lung Cancer

October 1st 2016

Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.

Dr. Pirker on New Clinical Trial Designs in Lung Cancer

September 30th 2016

Robert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.

EGFR-Targeted Approach Continues to Advance in NSCLC

September 30th 2016

Joshua Bauml, MD, discusses the evolution of EGFR-targeted therapies, resistance mutations in patients with non–small cell lung cancer, the evolution of next-generation sequencing, and ongoing trials that could have an impact in this space.

Dr. Powell on Important Future Directions in Lung Cancer

September 29th 2016

Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.